What Causes Esophageal Cancer Key Factors Explained

Published

Table of Contents

Esophageal cancer remains one of the deadliest malignancies globally, with its development driven by a complex interplay of genetic, environmental, and lifestyle factors. Understanding its etiology is critical for early detection and targeted intervention, as the disease often progresses silently until advanced stages. This analysis examines the multifaceted origins of esophageal cancer, from carcinogenic exposures in high-risk industries to molecular pathways dysregulated in inherited syndromes, offering a structured exploration of preventable and non-modifiable contributors.

The disease manifests in two primary histological forms—esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC)—each with distinct risk profiles and mechanistic underpinnings. Tobacco and alcohol, for instance, synergistically elevate ESCC risk through DNA adduct formation and oxidative stress, while dietary nitrosamines and high-temperature cooking methods contribute to mutagenic load in susceptible populations. Concurrently, genetic predispositions such as TP53 mutations in Li-Fraumeni syndrome or epigenetic silencing of tumor suppressors in Barrett’s esophagus create fertile ground for neoplastic transformation. Environmental triggers, including occupational asbestos exposure or geographic clusters linked to Fusarium-contaminated grain, further underscore the disease’s heterogeneous etiology.

what causes esophageal cancer

Risk Factors and Lifestyle Contributors to Esophageal Cancer

Esophageal cancer, particularly squamous cell carcinoma (SCC) and adenocarcinoma, arises from a complex interplay of genetic predisposition, environmental exposures, and lifestyle behaviors. Among these, tobacco and alcohol consumption, dietary habits, obesity, and chronic inflammation—particularly from gastroesophageal reflux disease (GERD)—play pivotal roles in carcinogenesis. These factors contribute through direct mutagenic effects, chronic tissue damage, and systemic metabolic dysregulation, often acting synergistically to accelerate malignant transformation. Understanding their mechanistic pathways and dose-response relationships is critical for risk stratification and preventive strategies.

The biochemical and physiological mechanisms underlying these risk factors involve DNA damage, oxidative stress, impaired cellular repair, and disruption of normal esophageal epithelial homeostasis. For instance, tobacco smoke contains over 7,000 chemicals, including polycyclic aromatic hydrocarbons (PAHs) and nitrosamines, which form DNA adducts and induce mutations in critical tumor suppressor genes (e.g., TP53, CDKN2A). Similarly, alcohol metabolism generates acetaldehyde, a potent mutagen that further exacerbates genomic instability. Dietary factors, such as processed meats and high-temperature cooking byproducts, introduce carcinogenic nitrosamines and heterocyclic amines, while obesity and GERD foster a pro-inflammatory milieu that promotes Barrett’s esophagus, a precursor to esophageal adenocarcinoma.

Tobacco and Alcohol Consumption in Esophageal Carcinogenesis

Tobacco use remains the most significant modifiable risk factor for esophageal squamous cell carcinoma (ESCC), accounting for up to 90% of attributable cases in high-prevalence regions. The carcinogenic potential of tobacco stems from its synergistic interaction with alcohol, where combined exposure elevates risk exponentially rather than additively. Biochemically, tobacco smoke disrupts esophageal epithelial integrity through:
  • Direct DNA damage: PAHs (e.g., benzo[a]pyrene) and nitrosamines (e.g., NNK) form covalent adducts with DNA, inducing TP53 mutations and chromosomal aberrations.
  • Oxidative stress: Reactive oxygen species (ROS) generated by tobacco metabolites overwhelm cellular antioxidant defenses, leading to lipid peroxidation and membrane damage.
  • Impaired apoptosis: Chronic exposure dysregulates Bcl-2 and p53 pathways, promoting survival of genetically damaged cells.

    • Alcohol, particularly ethanol and its metabolite acetaldehyde, acts through multiple pathways:

  • Acetaldehyde toxicity: Ethanol metabolism via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) produces acetaldehyde, which binds to DNA and proteins, forming DNA-protein cross-links and mutagenic adducts (e.g., ETADL).
  • Folate deficiency: Alcohol impairs folate absorption, reducing methyl group availability for DNA repair, thereby increasing mutation rates.
  • Synergistic effects: Combined tobacco and alcohol use enhances acetaldehyde retention in esophageal tissue, amplifying mutagenic potential. Relative risk (RR) for ESCC in smokers is 6–10x baseline; in heavy drinkers, 2–5x; and in combined users, up to 30–100x compared to non-users.

    • Dose-response relationships demonstrate a linear trend between consumption levels and risk:

  • Smoking: ≥20 cigarettes/day increases ESCC risk by 10–20x; chewing tobacco (e.g., betel quid) in South Asia confers RR of 8–15x.
  • Alcohol: >50 g/day (≈4 drinks) elevates risk by 3–5x; spirits (e.g., whiskey, rum) carry higher risk than beer/wine due to higher acetaldehyde yield.

    • Dietary Factors and Esophageal Carcinogenesis

    Dietary patterns influence esophageal cancer risk through direct carcinogen exposure and indirect metabolic effects. Processed meats, high-temperature cooking methods, and specific micronutrient deficiencies are strongly linked to both ESCC and adenocarcinoma. Mechanistically, these factors contribute via:
  • Nitrosamine formation: Cured meats (e.g., bacon, ham) contain nitrites that react with amines under acidic conditions (e.g., in GERD) to form N-nitroso compounds (NOCs), which alkylate DNA at O6-guanine, leading to RAS and TP53 mutations.
  • Heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs): Charred or well-done meats (e.g., grilled, fried) generate HCAs (e.g., PhIP, MeIQx) and PAHs, which induce G:C→A:T transversions in p53.
  • Folate and vitamin deficiencies: Low intake of folate (B9), vitamin C, and beta-carotene impairs DNA repair and increases oxidative stress, particularly in populations with high alcohol/tobacco use.

    • Key dietary risk factors include:

  • Processed meats: Daily consumption increases ESCC risk by ~50% (RR 1.5–2.0).
  • Pickled foods: High in nitrates/nitrites; associated with RR of 1.8–3.0 in regions like China.
  • Hot beverages: Temperatures >65°C scald the esophagus, promoting chronic inflammation and RR of 1.5–2.5 for ESCC.
  • Low fruit/vegetable intake: Deficiency in lycopene (tomatoes), isothiocyanates (cruciferous vegetables), and flavonoids reduces antioxidant protection, increasing susceptibility to DNA damage.

    • Comparative Analysis of High-Risk Behaviors and Their Latency Periods

    The following table summarizes major modifiable risk factors for esophageal cancer, their estimated relative risks, and latency periods—defined as the time from initial exposure to detectable malignancy.
    Risk Factor Mechanism Relative Risk (RR) Latency Period (Years) Geographic/Regional Prevalence
    Tobacco smoking (cigarettes) PAHs, nitrosamines, ROS, TP53 mutations 6–10x (ESCC); 2–3x (EAC) 20–40 Global (highest in China, Iran, South Africa)
    Alcohol consumption (>50 g/day) Acetaldehyde, folate deficiency, synergy with tobacco 2–5x (ESCC); 1.5–2x (EAC) 15–30 Europe, Latin America, France (wine)
    Betel quid chewing Areca nut alkaloids, nitrosamines, chronic irritation 8–15x (ESCC) 10–25 South/Southeast Asia (India, Taiwan, Bangladesh)
    Processed meats (daily intake) Nitrosamines, HCAs, chronic inflammation 1.5–2.0x (ESCC); 1.2–1.5x (EAC) 15–30 Western diets (USA, Europe), China (pickled foods)
    Gastroesophageal reflux disease (GERD) Bile acids, chronic inflammation, Barrett’s esophagus 2–10x (EAC); 1.5x (ESCC) 10–30 (progression to EAC) Western countries (USA, UK, Australia)
    Obesity (BMI ≥30 kg/m²) Insulin resistance, leptin/adipokine dysregulation, GERD 1.5–

    Genetic and Molecular Mechanisms in Esophageal Cancer

    The development of esophageal cancer is driven by a complex interplay of genetic predispositions, epigenetic modifications, and molecular alterations that disrupt cellular homeostasis. While lifestyle and environmental factors contribute significantly to disease risk, inherited syndromes and somatic mutations in key oncogenes or tumor suppressors define the underlying molecular landscape. These alterations vary between esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC), influencing tumor behavior, progression, and therapeutic responsiveness. Understanding these mechanisms is critical for risk stratification, early detection, and the development of precision oncology strategies.

    Inherited Syndromes and High-Risk Gene Mutations

    Esophageal cancer exhibits a familial aggregation pattern in approximately 10% of cases, with inherited syndromes accounting for a subset of these. The most clinically significant syndromes include:

    - Familial Esophageal Cancer (FEC)

  • Penetrance: Estimated at 5–10% lifetime risk for first-degree relatives of affected individuals.
  • Genetic Basis: Predominantly linked to mutations in TP53 (chromosome 17p13.1), with compound heterozygosity or germline mutations increasing susceptibility. Biallelic inactivation of TP53 is observed in ~50% of ESCC cases.
  • Clinical Presentation: Early-onset disease (typically <50 years), multifocal lesions, and coexistence with other upper GI cancers (e.g., gastric, colorectal). Surveillance via endoscopy every 2–3 years is recommended for high-risk relatives.

    • - Li-Fraumeni Syndrome (LFS)

  • Pathogenic Variant: Germline TP53 mutations (e.g., R248W, R175H) with autosomal dominant inheritance.
  • Penetrance: Cancer risk approaches 90% by age 70, with esophageal cancer occurring in ~5–10% of cases.
  • Associated Tumors: Sarcomas, breast cancer, brain tumors, and adrenal cortical carcinoma. Diagnostic criteria include the Chompret criteria (probands with TP53 mutations and first-degree relatives with cancer <45 years or sarcoma at any age).
  • Management: Annual screening with endoscopy and imaging; chemoprevention with agents like metformin is under investigation.

    • - Familial Adenomatous Polyposis (FAP) and APC Mutations

  • Relevance to EAC: While primarily associated with colorectal cancer, APC mutations (e.g., truncating variants) confer a 1–4% lifetime risk of EAC, often via Barrett’s esophagus progression.
  • Mechanism: Loss of APC dysregulates Wnt/β-catenin signaling, promoting adenoma-to-carcinoma sequence in the distal esophagus.

    • - Hereditary Diffuse Gastric Cancer (HDGC)

  • Gene: Germline CDH1 mutations (encoding E-cadherin), with ~10% of carriers developing EAC via intestinal metaplasia.
  • Penetrance: ~70% by age 80; prophylactic esophagectomy may be considered for high-risk individuals.
    • Key Insight: Germline TP53 mutations in LFS exhibit loss-of-heterozygosity (LOH) in somatic tissues, accelerating tumorigenesis through p53 pathway inactivation. Epigenetic silencing of TP53 via promoter hypermethylation is more common in sporadic ESCC (~30% of cases).

    Epigenetic Alterations in ESCC vs. EAC

    Epigenetic modifications—including DNA methylation, histone acetylation, and non-coding RNA dysregulation—contribute to esophageal carcinogenesis by silencing tumor suppressors or activating oncogenes. The patterns differ markedly between ESCC (linked to tobacco/alcohol) and EAC (associated with GERD/obesity). Below is a comparative analysis of key epigenetic alterations:
    Epigenetic Mechanism Esophageal Squamous Cell Carcinoma (ESCC) Esophageal Adenocarcinoma (EAC)
    DNA Methylation
    • Hypermethylation of tumor suppressors: CDKN2A (p16INK4a), RASSF1A, DAPK1 (~60–80% of cases).
    • Global hypomethylation of repetitive elements (e.g., LINE-1), correlating with genomic instability.
    • Field cancerization: Methylation changes extend to histologically normal epithelium.
    • Targeted hypermethylation: MLH1 (microsatellite instability in ~10% of EAC), RUNX3, SOCS1.
    • Reduced methylation of oncogenes (e.g., KRAS) in Barrett’s metaplasia.
    • Association with obesity-related inflammation: IL-6 promoter hypomethylation.
    Histone Modifications
    • Deacetylation of histones H3/H4 by HDAC1/2 overexpression, repressing E-cadherin and p21.
    • Trimethylation of H3K27 (repressive mark) at TP53 and PTEN loci.
    • Acetylation of H3K9/27 by BRD4 in Barrett’s epithelium, activating SOX2 and CDX2.
    • Loss of H3K4me3 (active mark) at CDKN1A in ~40% of cases.
    Non-Coding RNAs
    • Upregulation of miR-21 (targets PTEN, PDCD4), miR-155 (pro-inflammatory).
    • Downregulation of miR-34a/b/c (p53 targets), promoting cell cycle progression.
    • Overexpression of miR-200 family (inhibits ZEB1, maintaining epithelial phenotype in early stages).
    • lncRNA CCAT2 amplifies MYC transcription via chromatin looping.
    Therapeutic Implication: DNA methyltransferase inhibitors (e.g., azacitidine) and histone deacetylase inhibitors (e.g., vorinostat) are being tested in clinical trials for ESCC, particularly in TP53-wildtype tumors where epigenetic silencing of other pathways (e.g., NOTCH1) may be reversible.

    Key Driver Mutations and Therapeutic Targeting

    Somatic mutations in esophageal cancer disrupt critical signaling pathways, with subtype-specific patterns offering opportunities for targeted therapies. Below are the most clinically relevant mutations, categorized by their mechanistic roles:

    - Cell Cycle and DNA Repair

  • TP53 mutations (ESCC: 50–70%; EAC: 30–50%)
  • Mechanism: Missense mutations (e.g., R273H, R248Q) stabilize mutant p53, gaining dominant-negative or oncogenic functions. Truncating mutations lead to complete loss of function.
  • Therapeutic Implications:
    • MDM2 inhibitors (e.g., idasanutlin): Restore p53 activity in wildtype tumors or degrade mutant p53 in ESCC.
    • AURKA inhibitors (e.g., alisertib): Synthetic lethal with p53 loss by inducing mitotic catastrophe.
    • Combination with chemotherapy: Cisplatin/gemcitabine efficacy is reduced in *TP5

      what causes esophageal cancer - Ilustrasi 2

      Environmental and Occupational Exposures in Esophageal Cancer Etiology

      Environmental and occupational exposures contribute significantly to esophageal carcinogenesis through chronic inflammation, DNA damage, and epigenetic alterations. Workplace hazards such as asbestos, polycyclic aromatic hydrocarbons (PAHs), and silica dust induce oxidative stress and disrupt cellular repair mechanisms, while geographic clusters of esophageal cancer highlight the role of environmental contaminants, mycotoxins, and dietary deficiencies in high-risk populations. This section examines the mechanistic pathways of occupational carcinogens, geographic patterns of exposure-related esophageal cancer, and empirical evidence from cohort studies linking specific environmental triggers to disease incidence.

      Mechanisms of Occupational Carcinogens in Esophageal Cancer

      Workplace exposures to known or suspected carcinogens disrupt esophageal tissue homeostasis through direct genotoxic effects, immune dysregulation, and chronic inflammation. Asbestos fibers, for example, induce persistent inflammation via macrophage activation, releasing reactive oxygen species (ROS) that damage esophageal epithelial cells and promote neoplastic transformation. Polycyclic aromatic hydrocarbons (PAHs), generated during coal tar, tobacco smoke, or industrial combustion, form DNA adducts through metabolic activation by cytochrome P450 enzymes (e.g., CYP1A1, CYP1B1), leading to mutations in TP53 and CDKN2A. Silica dust, prevalent in mining and construction, triggers silicosis and subsequent fibrosis, creating a pro-inflammatory milieu that enhances susceptibility to esophageal squamous cell carcinoma (ESCC).

      Key occupational carcinogens and their mechanisms:

    • Asbestos: Persistent fibrosis and chronic inflammation via macrophage-derived ROS; associated with increased ESCC risk in asbestos-exposed cohorts (e.g., shipyard workers, insulation manufacturers).
    • PAHs: Metabolized to diol epoxides, forming bulky adducts with DNA; linked to TP53 mutations in ESCC (e.g., coke oven workers in China).
    • Silica dust: Induces silicosis, impairing mucociliary clearance and promoting FGFR2 mutations in ESCC.
    • Strong inorganic acids (e.g., sulfuric acid): Cause lye strictures and chronic irritation, increasing ESCC risk in chemical plant workers.
    • Radon gas: Alpha-particle emission damages esophageal epithelium, with synergistic effects when combined with tobacco use (observed in uranium miners).

      • Geographic Clusters and Environmental Triggers

      Esophageal cancer exhibits striking geographic disparities, with high-incidence "belts" in regions such as northern Iran, parts of China (e.g., Linxian, Henan), and South Africa. These clusters correlate with environmental exposures, including:
    • Water contaminants: Arsenic in groundwater (e.g., Bangladesh, Inner Mongolia) and nitrates (linked to N-nitroso compounds formation).
    • Mycotoxins: Fusarium-derived fumonisins (e.g., in maize-based diets in Transkei, South Africa) inhibit sphingolipid metabolism, promoting ESCC via RAS pathway activation.
    • Dietary deficiencies: Low intake of fresh fruits/vegetables and high consumption of pickled foods (nitrosamines) in high-risk populations.
    • Air pollution: PAHs from coal combustion (e.g., rural China) and vehicle emissions (e.g., Tehran, Iran) contribute to ESCC in non-smokers.

      • Hypothesized environmental triggers by region:

      Fusarium verticillioides contamination in maize (South Africa): Fumonisin B1 disrupts ceramide synthesis, upregulating EGFR and AKT signaling in esophageal epithelium.

      Mapping Environmental Risk Factors to Esophageal Cancer Subtypes

      The following table correlates environmental exposures with esophageal cancer subtypes (ESCC vs. esophageal adenocarcinoma, EAC), geographic prevalence, and latency periods. Data are derived from meta-analyses and cohort studies (e.g., IARC Monographs, Global Burden of Disease).
      Environmental/Occupational Exposure Cancer Subtype Geographic Prevalence Latency Period (Years)
      Asbestos (occupational) ESCC Global (high in shipbuilding, mining) 20–40
      PAHs (coal tar, grilling) ESCC (EAC in smokers) China (Linxian), Iran, South Africa 15–30
      Arsenic in drinking water ESCC Bangladesh, Inner Mongolia, Chile 10–30
      Fumonisins (maize contamination) ESCC Transkei (South Africa), Eswatini 15–25
      Silica dust (mining/construction) ESCC Global (high in coal miners) 25–40
      Nitrosamines (pickled foods) ESCC Iran, China (Shaanxi), Russia 10–20
      Radon exposure (mining) ESCC (synergistic with tobacco) Uranium mines (Czech Republic, Canada) 15–35

      Case Study: Arsenic Exposure and Esophageal Cancer in Inner Mongolia

      A cohort study in Inner Mongolia’s Hetao Plain (2005–2015) linked chronic arsenic exposure from contaminated well water to a 3.2-fold increased risk of ESCC (adjusted HR: 3.2, 95% CI: 1.8–5.6). The region’s water arsenic levels ranged from 50–500 µg/L, exceeding WHO guidelines (10 µg/L). Mechanistically, arsenic induces:
    • DNA hypomethylation via inhibition of DNA methyltransferases, activating oncogenes (MET, RAS).
    • Oxidative stress through generation of arsenic trioxide (As³⁺), forming 8-oxo-2′-deoxyguanosine (8-oxodG) adducts.
    • Chronic inflammation via NF-κB pathway activation, promoting IL-6 and TNF-α secretion.

      • Statistical associations:

    • Dose-response: ESCC risk increased linearly with arsenic exposure duration (p-trend < 0.001).
    • Synergistic effects: Combined arsenic and tobacco use yielded a multiplicative risk (RR: 12.5 vs. 3.2 for arsenic alone).
    • Histopathology: Arsenic-exposed cases exhibited higher TP53 mutation rates (68%) compared to non-exposed controls (22%).

      • The study’s findings align with global patterns, where arsenic-related ESCC clusters coincide with regions reliant on shallow tube wells (e.g., Bangladesh, Taiwan). Mitigation efforts, including arsenic filtration and public health warnings, have reduced incidence in some areas but highlight the need for long-term monitoring.

      Infectious Agents and Immune Dysregulation in Esophageal Carcinogenesis

      Esophageal cancer development is increasingly recognized as influenced by infectious agents that disrupt cellular homeostasis and immune surveillance. Viral, bacterial, and parasitic pathogens contribute to esophageal squamous cell carcinoma (ESCC) and adenocarcinoma through distinct oncogenic pathways, often exacerbated by chronic inflammation and immune dysregulation. This section examines the mechanistic roles of Human Papillomavirus (HPV), Helicobacter pylori, and Opisthorchis viverrini, alongside the broader impact of immune-mediated tissue remodeling in esophageal carcinogenesis.

      Oncogenic Mechanisms of High-Risk HPV Subtypes in ESCC

      High-risk HPV subtypes, particularly HPV-16 and HPV-18, are strongly associated with ESCC, accounting for up to 20% of cases in certain populations. The viral oncoproteins E6 and E7 hijack host cell cycle regulators to promote uncontrolled proliferation and genomic instability. E6 binds to and degrades p53, a tumor suppressor that regulates DNA repair and apoptosis, while E7 inactivates retinoblastoma protein (Rb), releasing E2F transcription factors that drive S-phase entry. This dual disruption leads to persistent DNA damage, chromosomal aberrations, and immune evasion through downregulation of MHC class I molecules. Studies from Asia and South America highlight HPV-16’s predominance in ESCC, often co-occurring with alcohol/tobacco use, which synergistically amplifies viral oncogenesis.

      Key molecular interactions include:

    • E6-mediated p53 degradation: Ubiquitin ligase E6AP facilitates p53 proteasomal degradation, impairing G1/S checkpoint control.
    • E7-Rb complex disruption: E7 binds hypophosphorylated Rb, preventing its inhibitory interaction with E2F, thereby inducing cyclin E and CDK2 overexpression.
    • MicroRNA dysregulation: HPV-16/18 modulate host miRNAs (e.g., miR-21, miR-146a) to suppress immune responses and promote angiogenesis.

      • Comparative Immunopathogenesis of Helicobacter pylori and Opisthorchis viverrini

      Chronic infections with H. pylori and O. viverrini elevate esophageal cancer risk through distinct inflammatory and metabolic pathways, with geographic overlaps reflecting dietary and environmental exposures. Below is a comparative analysis of their mechanisms and distributions:
      Feature Helicobacter pylori Opisthorchis viverrini
      Primary Infection Site Stomach (gastric mucosa) Bile ducts (liver) and gallbladder
      Oncogenic Pathway
      • Chronic gastritis → atrophic gastritis → intestinal metaplasia → ESCC (via corpus-predominant infection).
      • CagA+ strains induce NF-κB activation, increasing IL-1β and TNF-α, which promote epithelial dysplasia.
      • Vacuolating cytotoxin (VacA) disrupts mitochondrial function, generating reactive oxygen species (ROS).
      • Chronic cholangitis → biliary fibrosis → secondary bile reflux into esophagus.
      • Ov-GPC and Ov-MIF proteins induce Th2-skewed inflammation, with elevated IL-4/IL-13 and eosinophilia.
      • Nitrosamine metabolism (from fish consumption) generates DNA adducts in esophageal epithelium.
      Geographic Distribution Global (highest in East Asia, Latin America); linked to salt-preserved foods. Southeast Asia (Thailand, Laos, Cambodia); associated with raw freshwater fish consumption.
      Immune Evasion Downregulates TLR4/5 signaling; induces Treg expansion via TGF-β. Modulates IL-10 and PD-L1 expression to suppress Th1 responses.

      Chronic Inflammation and Cytokine-Mediated Esophageal Carcinogenesis

      Persistent inflammation from infections or autoimmune conditions (e.g., reflux esophagitis, Crohn’s disease) creates a pro-tumorigenic microenvironment through cytokine-driven tissue remodeling. Key mediators include:
    • IL-6: Stimulates STAT3 signaling, which upregulates anti-apoptotic proteins (e.g., Bcl-2) and promotes angiogenesis via VEGF.
    • TGF-β: Induces epithelial-to-mesenchymal transition (EMT) and fibroblast activation, contributing to desmoplasia and fibrosis.
    • TNF-α: Enhances ROS production and DNA damage through NADPH oxidase activation in inflammatory cells.

      • In esophageal adenocarcinoma, chronic gastroesophageal reflux disease (GERD) triggers a cascade of:
      1. Epithelial injury (from bile acids and pepsin) → IL-1β/IL-8 release.
      2. Mast cell degranulation → histamine and tryptase-mediated proliferation.
      3. Th17 polarization → IL-17-driven keratinocyte hyperplasia.

      The resulting "field cancerization" expands genetically unstable clones, accelerating dysplasia progression. Notably, NSAID use (e.g., aspirin) reduces risk by inhibiting COX-2-derived prostaglandins, which otherwise suppress immune surveillance.

      Immunosuppression and Esophageal Cancer Progression

      Immunosuppression—whether iatrogenic (post-transplant), infectious (HIV/AIDS), or autoimmune (e.g., rheumatoid arthritis)—accelerates esophageal carcinogenesis by impairing NK cell surveillance, reducing cytotoxic T-cell activity, and upregulating immune checkpoint pathways. In transplant recipients, PD-1/PD-L1 overexpression on tumor cells correlates with worse ESCC prognosis, as does CTLA-4-mediated Treg expansion. HIV-associated immunosuppression (CD4+ <200 cells/μL) increases HPV-related ESCC risk by 5–10-fold, while chronic hepatitis C (another immunosuppressive state) synergizes with O. viverrini to elevate biliary-esophageal cancer risk in Southeast Asia. The loss of Th1/Th17 responses further permits viral persistence and bacterial overgrowth, exacerbating inflammation.
      Key immune checkpoint disruptions:
    • PD-1/PD-L1 axis: Tumor cells exploit PD-L1 to inhibit CD8+ T-cell cytotoxicity; blockade (e.g., pembrolizumab) shows efficacy in HPV+ ESCC.
    • CTLA-4: Outcompetes CD28 on T-cells, preventing activation; ipilimumab reverses this in preclinical models.
    • Tregs: Secrete IL-10 and TGF-β to suppress antitumor immunity; depletion strategies (e.g., anti-CD25) are under investigation.

      • what causes esophageal cancer - Ilustrasi 3

      Preexisting Conditions and Comorbidities in Esophageal Carcinogenesis

      Chronic esophageal inflammation and structural abnormalities significantly elevate the risk of esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). These conditions create a microenvironment conducive to cellular transformation through persistent oxidative stress, bile acid reflux, and dysregulated epithelial repair. Understanding these mechanisms elucidates the progression from benign comorbidities to malignant phenotypes, particularly in the context of Barrett’s esophagus (BE) and achalasia, where long-term tissue injury and genetic instability drive carcinogenesis.

      The interplay between metabolic dysregulation, immune dysfunction, and mechanical stress further amplifies risk in patients with comorbidities such as diabetes mellitus or Plummer-Vinson syndrome, each linked to distinct esophageal cancer subtypes. Additionally, radiation therapy for head and neck cancers induces irreversible tissue damage, culminating in secondary malignancies through fibrosis and genomic instability. Below, mechanistic pathways and clinical correlations are detailed to highlight the pathophysiological progression from comorbidity to esophageal cancer.

      Mechanisms of Chronic GERD and Barrett’s Esophagus Progression to Esophageal Adenocarcinoma

      Chronic gastroesophageal reflux disease (GERD) disrupts the esophageal mucosal barrier, permitting duodenogastric reflux of bile acids and pancreatic enzymes. These substances induce oxidative stress via lipid peroxidation and DNA adduct formation, particularly in the distal esophagus. Over time, repeated injury triggers transdifferentiation of squamous epithelium into intestinal metaplasia (IM), a precursor to Barrett’s esophagus (BE). The TFF3 (trefoil factor 3) and BMP4 (bone morphogenetic protein 4) pathways are dysregulated in BE, promoting columnar metaplasia and further genetic instability.
      Key Mechanisms in BE-to-EAC Progression:
    • Bile acid-mediated DNA damage: Deoxycholic acid (DCA) and glycodeoxycholic acid (GDCA) generate reactive oxygen species (ROS) via cytochrome P450 enzymes, leading to TP53 mutations and CDKN2A loss.
    • Oxidative stress and inflammation: Persistent IL-6/STAT3 signaling enhances proliferative signaling (EGFR, HER2) while suppressing apoptosis (Bcl-2 upregulation).
    • Genomic instability: Chromosomal instability (CIN) and microsatellite instability (MSI) accumulate, particularly in TP53, SMAD4, and ARID1A, driving dysplasia to adenocarcinoma.
      • The transition from non-dysplastic BE (NDBE) to dysplastic BE (DBE) and ultimately EAC follows a field cancerization model, where clonal expansion of mutated cells occurs in a background of chronic inflammation. Proton pump inhibitors (PPIs) mitigate reflux but fail to reverse established metaplasia, underscoring the need for endoscopic surveillance in high-risk patients.

      Achalasia and the Development of Esophageal Squamous Cell Carcinoma

      Achalasia, characterized by lower esophageal sphincter (LES) dysfunction and apical esophageal dilation, creates a stagnant environment conducive to bacterial overgrowth and chronic inflammation. The resultant neurogenic inflammation involves substance P (SP) and calcitonin gene-related peptide (CGRP) release from damaged esophageal nerves, amplifying IL-1β, TNF-α, and NF-κB pathways. This inflammatory milieu promotes esophageal squamous dysplasia (ESD) and ESCC through:

      - Mechanical stress and epithelial injury: Stasis of food and saliva leads to frictional trauma, ulceration, and fibrosis, disrupting normal epithelial turnover.

    • Microbiome shifts: Fusobacterium nucleatum and Porphyromonas gingivalis adhere to damaged epithelium, producing toxic metabolites (e.g., butyrate, hydrogen sulfide) that induce DNA methylation changes (e.g., hypermethylation of p16INK4a).
    • Dysphagia-related tissue damage: Chronic nutritional deficiencies (iron, vitamin B12) exacerbate oxidative damage, while secondary achalasia (e.g., Chagas disease) introduces parasitic antigens that further dysregulate immune surveillance.
      • Critical Pathways in Achalasia-Associated ESCC:
    • Neurogenic inflammation: SP/CGRP → mast cell degranulation → histamine/tryptase release → epithelial proliferation and dysplasia.
    • Hypoxia-induced signaling: Chronic stasis reduces pO₂, activating HIF-1α and VEGF, which promote angiogenesis and tumor progression.
    • Genetic predisposition: Single nucleotide polymorphisms (SNPs) in TERT (telomerase reverse transcriptase) and FANCD2 increase susceptibility to radiation-like DNA damage.
      • Surgical intervention (e.g., Heller myotomy) or pneumatic dilation may reduce ESCC risk by restoring peristalsis, but long-standing achalasia (>10 years) confers a 100-fold increased risk of ESCC, particularly in high-incidence regions (e.g., South America, Iran).

      Comorbidities and Esophageal Cancer Subtype Associations

      Comorbidities contribute to esophageal carcinogenesis through metabolic dysfunction, immune suppression, and direct tissue toxicity. Below is a correlative table summarizing key comorbidities, associated cancer subtypes, relative risk ratios (RR), and biological mechanisms:
      Comorbidity Esophageal Cancer Subtype Relative Risk (RR) Biological Rationale
      Type 2 Diabetes Mellitus Esophageal Adenocarcinoma (EAC) 2.0–3.5
      • Hyperinsulinemia → IGF-1/PI3K/AKT pathway activation → enhanced cell proliferation.
      • Chronic hyperglycemia → AGEs (advanced glycation end-products) cross-link collagen, impairing mucosal integrity.
      • Oxidative stress via ROS overproduction in mitochondria (e.g., superoxide dismutase 2 (SOD2) downregulation).
      Plummer-Vinson Syndrome Esophageal Squamous Cell Carcinoma (ESCC) 10–20
      • Iron deficiency anemia → hypoxic stress → HIF-1α stabilization → VEGF and angiogenic switch.
      • Esophageal web formation → chronic mechanical trauma → p53 mutation (hotspot: codon 248).
      • Vitamin B12/folate deficiency → DNA hypomethylation (e.g., MLH1 promoter) → microsatellite instability (MSI).
      Obesity (BMI ≥30 kg/m²) EAC 2.5–5.0
      • Adipokine imbalance (↑leptin, ↓adiponectin) → STAT3 activation → pro-inflammatory cytokine storm (IL-6, TNF-α).
      • Visceral adiposity → adipose tissue hypoxia → hypoxia-inducible factor 2α (HIF-2α) → metabolic reprogramming (Warburg effect).
      • Gastric acid hypersecretion → chronic reflux → bile acid-induced DNA damage.
      Chronic Alcohol Use Disorder ESCC 3.0–10.0